5th Nov 2015 11:10
LONDON (Alliance News) - Oxford Pharmascience Group PLC on Thursday said it has completed a proof-of-concept study for using its OXPzero technology in ibuprofen, the painkiller.
The data found OXPzero ibuprofen delivers benefits beyond existing ibuprofen products, including reducing the incidence of gastrointestinal mucosal damage and masking the bitterness of the drug's taste.
"We are very pleased with the data package on OXPzeroTM Ibuprofen which demonstrates this is a compound with potential to disrupt the market, delivering a range of key benefits that provide clear and compelling differentiation," said Marcelo Bravo, Oxford Pharmascience's chief executive.
Shares in Oxford Pharmascience were up 6.7% to 6.399 pence on Thursday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Pharmascience Group